|
Firmonertinib 80mg qd oral for 8 weeks. Clinical Trials
1 actively recruiting trial
Also known as: AST-2818
Pipeline
Phase 2: 1
Top Sponsors
- Peking University Cancer Hospital & Institute1
Indications
- EGFR Positive Non-small Cell Lung Cancer1
- NSCLC1
- Lung Cancer1
- Neoadjuvant Therapy1
- Cancer1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.